Merck: Keytruda drug fails bladder cancer trial
(CercleFinance.com) - Merck said on Wednesday that its Keytruda cancer drug has failed to meet its primary endpoints for patients with bladder cancer in a late-stage clinical trial.
Merck's immunotherapy for the first-line treatment of patients with advanced or metastatic urothelial carcinoma did not meet its pre-specified dual primary endpoints of overall survival or progression-free survival compared with chemotherapy, the US drugmaker said in a statement.
Keytruda - which boosts the body's immune system's ability to detect and fight tumor cells - has been approved in many indications spanning from non-small cell lung cancer to classical Hodgkin lymphoma.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Merck's immunotherapy for the first-line treatment of patients with advanced or metastatic urothelial carcinoma did not meet its pre-specified dual primary endpoints of overall survival or progression-free survival compared with chemotherapy, the US drugmaker said in a statement.
Keytruda - which boosts the body's immune system's ability to detect and fight tumor cells - has been approved in many indications spanning from non-small cell lung cancer to classical Hodgkin lymphoma.
Copyright (c) 2020 CercleFinance.com. All rights reserved.